Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $15.19, but opened at $14.52. Astellas Pharma shares last traded at $15.03, with a volume of 9,093 shares trading hands.
Analysts Set New Price Targets
Separately, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.
Get Our Latest Analysis on Astellas Pharma
Astellas Pharma Stock Performance
Astellas Pharma Company Profile
Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions.
The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes.
Further Reading
- Five stocks we like better than Astellas Pharma
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
- Braze Beat Expectations—Now 2 SaaS Peers Are in Focus
- 3 Zero-Fee ETFs Worth More Than Their Cost
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
